Beijing Beilu Pharmaceutical (300016) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.66 Million ≈ $10.93 Million USD) by net assets (CN¥2.37 Billion ≈ $346.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300016 equity to assets ratio to measure how much of total assets are equity-financed.

Beijing Beilu Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Beijing Beilu Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Beijing Beilu Pharmaceutical earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Beijing Beilu Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Lander Sports Development Co Ltd
SHE:000558
-0.135x
Harum Energy Tbk PT
JK:HRUM
0.217x
Shenzhen Textile Holdings Co Ltd
SHE:000045
-0.037x
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMII
0.000x
Tiptree Inc
NASDAQ:TIPT
-0.024x
Gladstone Investment Corporation
NASDAQ:GAIN
-0.228x
Hypoport SE
XETRA:HYQ
0.012x
Zhejiang He Chuan Technology Corp. Ltd. A
SHG:688320
N/A

Annual Cash Flow Conversion Efficiency for Beijing Beilu Pharmaceutical (2006–2024)

The table below shows the annual cash flow conversion efficiency of Beijing Beilu Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Beilu Pharmaceutical market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.83 Billion
≈ $267.71 Million
CN¥163.02 Million
≈ $23.86 Million
0.089x +172.27%
2023-12-31 CN¥1.79 Billion
≈ $261.39 Million
CN¥58.46 Million
≈ $8.55 Million
0.033x -50.75%
2022-12-31 CN¥1.92 Billion
≈ $281.43 Million
CN¥127.81 Million
≈ $18.70 Million
0.066x +27.42%
2021-12-31 CN¥2.08 Billion
≈ $305.05 Million
CN¥108.73 Million
≈ $15.91 Million
0.052x -43.93%
2020-12-31 CN¥1.89 Billion
≈ $276.87 Million
CN¥176.00 Million
≈ $25.75 Million
0.093x -13.95%
2019-12-31 CN¥1.45 Billion
≈ $212.25 Million
CN¥156.81 Million
≈ $22.95 Million
0.108x -25.83%
2018-12-31 CN¥1.21 Billion
≈ $176.45 Million
CN¥175.75 Million
≈ $25.72 Million
0.146x +7.54%
2017-12-31 CN¥1.07 Billion
≈ $156.46 Million
CN¥144.92 Million
≈ $21.21 Million
0.136x +60.46%
2016-12-31 CN¥901.69 Million
≈ $131.95 Million
CN¥76.17 Million
≈ $11.15 Million
0.084x -2.56%
2015-12-31 CN¥932.63 Million
≈ $136.47 Million
CN¥80.85 Million
≈ $11.83 Million
0.087x +37.19%
2014-12-31 CN¥666.33 Million
≈ $97.51 Million
CN¥42.11 Million
≈ $6.16 Million
0.063x -14.55%
2013-12-31 CN¥559.38 Million
≈ $81.86 Million
CN¥41.37 Million
≈ $6.05 Million
0.074x +69.54%
2012-12-31 CN¥523.96 Million
≈ $76.67 Million
CN¥22.86 Million
≈ $3.34 Million
0.044x -53.12%
2011-12-31 CN¥491.47 Million
≈ $71.92 Million
CN¥45.73 Million
≈ $6.69 Million
0.093x +15.98%
2010-12-31 CN¥467.62 Million
≈ $68.43 Million
CN¥37.51 Million
≈ $5.49 Million
0.080x -39.92%
2009-12-31 CN¥433.71 Million
≈ $63.46 Million
CN¥57.91 Million
≈ $8.47 Million
0.134x +473.67%
2008-12-31 CN¥133.23 Million
≈ $19.50 Million
CN¥-4.76 Million
≈ $-696.67K
-0.036x -126.30%
2007-12-31 CN¥90.33 Million
≈ $13.22 Million
CN¥12.28 Million
≈ $1.80 Million
0.136x -50.49%
2006-12-31 CN¥71.59 Million
≈ $10.48 Million
CN¥19.65 Million
≈ $2.88 Million
0.274x --

About Beijing Beilu Pharmaceutical

SHE:300016 China Drug Manufacturers - Specialty & Generic
Market Cap
$643.28 Million
CN¥4.40 Billion CNY
Market Cap Rank
#10806 Global
#2903 in China
Share Price
CN¥7.81
Change (1 day)
+2.63%
52-Week Range
CN¥7.23 - CN¥11.26
All Time High
CN¥27.25
About

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more